Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database

Despite the routine use of novel therapeutic agents multiple myeloma (MM) remains an incurable malignancy. The MAMMOTH study reported that patients refractory to anti-CD38 monoclonal antibodies (mAbs) have particularly dismal outcomes in the United States (Gandhi et al. Leukemia 2019). Given the differences in drug accessibility with our publicly funded healthcare model, there is a need to understand the real-world outcomes of patients refractory to anti-CD38 mAbs, particularly those that are triple class refractory (TCR), in the Canadian context. We performed a retrospective cohort study to describe the characteristics, progression free survival (PFS), and overall survival (OS) of patients treated for MM refractory to anti-CD38 mAb therapy.